{"transactions":[{"id":1035986,"issuer":{"id":1039,"kind":"organization","name":"Rocket Lab Corp","symbol":"RKLB"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T00:28:21.000Z","date":"2025-09-16","kind":"other","planned":false,"acquired":false,"shares":164026,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"SST Capital Management, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F13","text":"Represents shares received by SST Capital Management, LLC pursuant to pro rata distributions by DCVC IV and DCVC Opportunity Fund II, for no consideration, of shares of Common Stock to their respective partners and such partners' members, as applicable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are held of record by SST Capital Management, LLC of which the Reporting Person is a beneficial owner. The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":164026,"source":{"system":"sec-edgar","filing":"0001104659-25-091375","document":"tm2526461-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1819994/000110465925091375/tm2526461-1_4seq1.xml","form_type":"4"}},{"id":1035985,"issuer":{"id":1039,"kind":"organization","name":"Rocket Lab Corp","symbol":"RKLB"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T00:28:21.000Z","date":"2025-09-16","kind":"other","planned":false,"acquired":false,"shares":9894,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Three Kingdoms Capital Partners, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"Represents shares received by Three Kingdoms Capital Partners, LP pursuant to pro rata distributions by DCVC IV and DCVC Opportunity Fund II, for no consideration, of shares of Common Stock to their respective partners and such partners' members, as applicable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"The shares are held of record by Three Kingdoms Capital Partners, LP of which the Reporting Person is an indirect member of the general\npartner. The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":9894,"source":{"system":"sec-edgar","filing":"0001104659-25-091375","document":"tm2526461-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1819994/000110465925091375/tm2526461-1_4seq1.xml","form_type":"4"}},{"id":1035984,"issuer":{"id":1039,"kind":"organization","name":"Rocket Lab Corp","symbol":"RKLB"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T00:28:21.000Z","date":"2025-09-16","kind":"other","planned":false,"acquired":false,"shares":1331569,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"On September 16, 2025, DCVC Opportunity Fund II distributed, for no consideration, 1,331,569 shares of Common Stock (the \"DCVC Opportunity Fund II Shares\") to its limited partners and to DCVC Opportunity Fund II GP, the general partner of DCVC Opportunity Fund II, representing each such partner's pro rata interest in such DCVC Opportunity Fund II Shares. DCVC Opportunity Fund II GP then distributed, for no consideration, the DCVC Opportunity Fund II Shares it received in the distribution by DCVC Opportunity Fund II to its members, representing each such member's pro rata interest in such DCVC Opportunity Fund II Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents securities held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opportunity Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opportunity Fund II GP\") is the general partner of DCVC Opportunity Fund II and has sole voting and dispositive power with regard to the securities held by DCVC Opportunity Fund II. The Reporting Person is a managing member of DCVC Opportunity Fund II GP and shares voting and dispositive power with respect to the securities held by DCVC Opportunity Fund II. The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-091375","document":"tm2526461-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1819994/000110465925091375/tm2526461-1_4seq1.xml","form_type":"4"}},{"id":1035983,"issuer":{"id":1039,"kind":"organization","name":"Rocket Lab Corp","symbol":"RKLB"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T00:28:21.000Z","date":"2025-09-16","kind":"other","planned":false,"acquired":false,"shares":541526,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"On September 16, 2025, DCVC IV distributed, for no consideration, 541,526 shares of Common Stock (the \"DCVC IV Shares\") to its limited partners and to DCVC IV GP, the general partner of DCVC IV, representing each such partner's pro rata interest in such DCVC IV Shares. DCVC IV GP then distributed, for no consideration, the DCVC IV Shares it received in the distribution by DCVC IV to its members, representing each such member's pro rata interest in such DCVC IV Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the securities held by DCVC IV. The Reporting Person is a managing member of DCVC IV GP and shares voting and dispositive power with respect to the securities held by DCVC IV. The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-091375","document":"tm2526461-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1819994/000110465925091375/tm2526461-1_4seq1.xml","form_type":"4"}},{"id":1035982,"issuer":{"id":1039,"kind":"organization","name":"Rocket Lab Corp","symbol":"RKLB"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T00:28:21.000Z","date":"2025-09-16","kind":"sale","planned":false,"acquired":false,"shares":24955,"price":52.2274,"value":1303334.767,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in column 4 is a weighted average price of the aggregate number of shares sold. These shares were sold in multiple transactions at prices ranging from $52.10 to $52.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents securities held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opportunity Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opportunity Fund II GP\") is the general partner of DCVC Opportunity Fund II and has sole voting and dispositive power with regard to the securities held by DCVC Opportunity Fund II. The Reporting Person is a managing member of DCVC Opportunity Fund II GP and shares voting and dispositive power with respect to the securities held by DCVC Opportunity Fund II. The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":1331569,"source":{"system":"sec-edgar","filing":"0001104659-25-091375","document":"tm2526461-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1819994/000110465925091375/tm2526461-1_4seq1.xml","form_type":"4"}},{"id":1035981,"issuer":{"id":1039,"kind":"organization","name":"Rocket Lab Corp","symbol":"RKLB"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T00:28:21.000Z","date":"2025-09-16","kind":"sale","planned":false,"acquired":false,"shares":10148,"price":52.2274,"value":530003.6552,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in column 4 is a weighted average price of the aggregate number of shares sold. These shares were sold in multiple transactions at prices ranging from $52.10 to $52.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the securities held by DCVC IV. The Reporting Person is a managing member of DCVC IV GP and shares voting and dispositive power with respect to the securities held by DCVC IV. The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":541526,"source":{"system":"sec-edgar","filing":"0001104659-25-091375","document":"tm2526461-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1819994/000110465925091375/tm2526461-1_4seq1.xml","form_type":"4"}},{"id":1035980,"issuer":{"id":1039,"kind":"organization","name":"Rocket Lab Corp","symbol":"RKLB"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T00:28:21.000Z","date":"2025-09-16","kind":"sale","planned":false,"acquired":false,"shares":22130,"price":51.7871,"value":1146048.523,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in column 4 is a weighted average price of the aggregate number of shares sold. These shares were sold in multiple transactions at prices ranging from $51.10 to $52.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents securities held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opportunity Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opportunity Fund II GP\") is the general partner of DCVC Opportunity Fund II and has sole voting and dispositive power with regard to the securities held by DCVC Opportunity Fund II. The Reporting Person is a managing member of DCVC Opportunity Fund II GP and shares voting and dispositive power with respect to the securities held by DCVC Opportunity Fund II. The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":1356524,"source":{"system":"sec-edgar","filing":"0001104659-25-091375","document":"tm2526461-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1819994/000110465925091375/tm2526461-1_4seq1.xml","form_type":"4"}},{"id":1035979,"issuer":{"id":1039,"kind":"organization","name":"Rocket Lab Corp","symbol":"RKLB"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T00:28:21.000Z","date":"2025-09-16","kind":"sale","planned":false,"acquired":false,"shares":9000,"price":51.7871,"value":466083.9,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in column 4 is a weighted average price of the aggregate number of shares sold. These shares were sold in multiple transactions at prices ranging from $51.10 to $52.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the securities held by DCVC IV. The Reporting Person is a managing member of DCVC IV GP and shares voting and dispositive power with respect to the securities held by DCVC IV. The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":551674,"source":{"system":"sec-edgar","filing":"0001104659-25-091375","document":"tm2526461-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1819994/000110465925091375/tm2526461-1_4seq1.xml","form_type":"4"}},{"id":1035978,"issuer":{"id":1039,"kind":"organization","name":"Rocket Lab Corp","symbol":"RKLB"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T00:28:21.000Z","date":"2025-09-16","kind":"sale","planned":false,"acquired":false,"shares":31948,"price":50.2431,"value":1605166.5588,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in column 4 is a weighted average price of the aggregate number of shares sold. These shares were sold in multiple transactions at prices ranging from $50.02 to $50.398, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents securities held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opportunity Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opportunity Fund II GP\") is the general partner of DCVC Opportunity Fund II and has sole voting and dispositive power with regard to the securities held by DCVC Opportunity Fund II. The Reporting Person is a managing member of DCVC Opportunity Fund II GP and shares voting and dispositive power with respect to the securities held by DCVC Opportunity Fund II. The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":1378654,"source":{"system":"sec-edgar","filing":"0001104659-25-091375","document":"tm2526461-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1819994/000110465925091375/tm2526461-1_4seq1.xml","form_type":"4"}},{"id":1035977,"issuer":{"id":1039,"kind":"organization","name":"Rocket Lab Corp","symbol":"RKLB"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T00:28:21.000Z","date":"2025-09-16","kind":"sale","planned":false,"acquired":false,"shares":12993,"price":50.2431,"value":652808.5983,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in column 4 is a weighted average price of the aggregate number of shares sold. These shares were sold in multiple transactions at prices ranging from $50.02 to $50.398, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the securities held by DCVC IV. The Reporting Person is a managing member of DCVC IV GP and shares voting and dispositive power with respect to the securities held by DCVC IV. The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":560674,"source":{"system":"sec-edgar","filing":"0001104659-25-091375","document":"tm2526461-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1819994/000110465925091375/tm2526461-1_4seq1.xml","form_type":"4"}},{"id":1035976,"issuer":{"id":1039,"kind":"organization","name":"Rocket Lab Corp","symbol":"RKLB"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T00:28:21.000Z","date":"2025-09-16","kind":"sale","planned":false,"acquired":false,"shares":165753,"price":49.2372,"value":8161213.6116,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in column 4 is a weighted average price of the aggregate number of shares sold. These shares were sold in multiple transactions at prices ranging from $49.015 to $50.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents securities held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opportunity Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opportunity Fund II GP\") is the general partner of DCVC Opportunity Fund II and has sole voting and dispositive power with regard to the securities held by DCVC Opportunity Fund II. The Reporting Person is a managing member of DCVC Opportunity Fund II GP and shares voting and dispositive power with respect to the securities held by DCVC Opportunity Fund II. The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":1410602,"source":{"system":"sec-edgar","filing":"0001104659-25-091375","document":"tm2526461-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1819994/000110465925091375/tm2526461-1_4seq1.xml","form_type":"4"}},{"id":1035975,"issuer":{"id":1039,"kind":"organization","name":"Rocket Lab Corp","symbol":"RKLB"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T00:28:21.000Z","date":"2025-09-16","kind":"sale","planned":false,"acquired":false,"shares":67409,"price":49.2372,"value":3319030.4148,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in column 4 is a weighted average price of the aggregate number of shares sold. These shares were sold in multiple transactions at prices ranging from $49.015 to $50.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the securities held by DCVC IV. The Reporting Person is a managing member of DCVC IV GP and shares voting and dispositive power with respect to the securities held by DCVC IV. The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":573667,"source":{"system":"sec-edgar","filing":"0001104659-25-091375","document":"tm2526461-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1819994/000110465925091375/tm2526461-1_4seq1.xml","form_type":"4"}},{"id":1035974,"issuer":{"id":1039,"kind":"organization","name":"Rocket Lab Corp","symbol":"RKLB"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T00:28:21.000Z","date":"2025-09-16","kind":"sale","planned":false,"acquired":false,"shares":341545,"price":48.5271,"value":16574188.3695,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average price of the aggregate number of shares sold. These shares were sold in multiple transactions at prices ranging from $48.013 to $49.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents securities held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opportunity Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opportunity Fund II GP\") is the general partner of DCVC Opportunity Fund II and has sole voting and dispositive power with regard to the securities held by DCVC Opportunity Fund II. The Reporting Person is a managing member of DCVC Opportunity Fund II GP and shares voting and dispositive power with respect to the securities held by DCVC Opportunity Fund II. The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":1576355,"source":{"system":"sec-edgar","filing":"0001104659-25-091375","document":"tm2526461-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1819994/000110465925091375/tm2526461-1_4seq1.xml","form_type":"4"}},{"id":1035973,"issuer":{"id":1039,"kind":"organization","name":"Rocket Lab Corp","symbol":"RKLB"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T00:28:21.000Z","date":"2025-09-16","kind":"sale","planned":false,"acquired":false,"shares":138901,"price":48.5271,"value":6740462.7171,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average price of the aggregate number of shares sold. These shares were sold in multiple transactions at prices ranging from $48.013 to $49.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the securities held by DCVC IV. The Reporting Person is a managing member of DCVC IV GP and shares voting and dispositive power with respect to the securities held by DCVC IV. The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":641076,"source":{"system":"sec-edgar","filing":"0001104659-25-091375","document":"tm2526461-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819994/000110465925091375/tm2526461-1_4seq1.xml","form_type":"4"}},{"id":1035972,"issuer":{"id":1039,"kind":"organization","name":"Rocket Lab Corp","symbol":"RKLB"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T00:28:21.000Z","date":"2025-09-16","kind":"sale","planned":false,"acquired":false,"shares":745239,"price":47.4874,"value":35389462.4886,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price of the aggregate number of shares sold. These shares were sold in multiple transactions at prices ranging from $47.013 to $48.01, inclusive. The Reporting Person undertakes to provide to Rocket Lab Corporation (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents securities held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opportunity Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opportunity Fund II GP\") is the general partner of DCVC Opportunity Fund II and has sole voting and dispositive power with regard to the securities held by DCVC Opportunity Fund II. The Reporting Person is a managing member of DCVC Opportunity Fund II GP and shares voting and dispositive power with respect to the securities held by DCVC Opportunity Fund II. The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":1917900,"source":{"system":"sec-edgar","filing":"0001104659-25-091375","document":"tm2526461-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819994/000110465925091375/tm2526461-1_4seq1.xml","form_type":"4"}},{"id":1035971,"issuer":{"id":1039,"kind":"organization","name":"Rocket Lab Corp","symbol":"RKLB"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T00:28:21.000Z","date":"2025-09-16","kind":"sale","planned":false,"acquired":false,"shares":303076,"price":47.4874,"value":14392291.2424,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price of the aggregate number of shares sold. These shares were sold in multiple transactions at prices ranging from $47.013 to $48.01, inclusive. The Reporting Person undertakes to provide to Rocket Lab Corporation (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the securities held by DCVC IV. The Reporting Person is a managing member of DCVC IV GP and shares voting and dispositive power with respect to the securities held by DCVC IV. The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":779977,"source":{"system":"sec-edgar","filing":"0001104659-25-091375","document":"tm2526461-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819994/000110465925091375/tm2526461-1_4seq1.xml","form_type":"4"}},{"id":1105871,"issuer":{"id":1039,"kind":"organization","name":"Rocket Lab Corp","symbol":"RKLB"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-18T17:39:54.000Z","date":"2025-06-13","kind":"sale","planned":false,"acquired":false,"shares":582932,"price":26.0067,"value":15160137.6444,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average price of the aggregate number of shares sold. These shares were sold in multiple transactions with 819,184 shares sold at prices ranging from $25.4500 to $26.4400 and 816 shares sold at prices ranging from $26.4600 to $26.5000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents securities held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opportunity Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opportunity Fund II GP\") is the general partner of DCVC Opportunity Fund II and has sole voting and dispositive power with regard to the securities held by DCVC Opportunity Fund II. The Reporting Person is a managing member of DCVC Opportunity Fund II GP and shares voting and dispositive power with respect to the securities held by DCVC Opportunity Fund II. The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":2663139,"source":{"system":"sec-edgar","filing":"0000950170-25-087771","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1819994/000095017025087771/ownership.xml","form_type":"4"}},{"id":1105870,"issuer":{"id":1039,"kind":"organization","name":"Rocket Lab Corp","symbol":"RKLB"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-18T17:39:54.000Z","date":"2025-06-13","kind":"sale","planned":false,"acquired":false,"shares":237068,"price":26.0067,"value":6165356.3556,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average price of the aggregate number of shares sold. These shares were sold in multiple transactions with 819,184 shares sold at prices ranging from $25.4500 to $26.4400 and 816 shares sold at prices ranging from $26.4600 to $26.5000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the securities held by DCVC IV. The Reporting Person is a managing member of DCVC IV GP and shares voting and dispositive power with respect to the securities held by DCVC IV. The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":1083053,"source":{"system":"sec-edgar","filing":"0000950170-25-087771","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819994/000095017025087771/ownership.xml","form_type":"4"}},{"id":1105869,"issuer":{"id":1039,"kind":"organization","name":"Rocket Lab Corp","symbol":"RKLB"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-18T17:39:54.000Z","date":"2025-06-12","kind":"sale","planned":false,"acquired":false,"shares":142178,"price":26.4437,"value":3759712.3786,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price of the aggregate number of shares sold. These shares were sold in multiple transactions at prices ranging from $26.3750 to $26.6300, inclusive. The Reporting Person undertakes to provide to Rocket Lab Corporation (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents securities held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opportunity Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opportunity Fund II GP\") is the general partner of DCVC Opportunity Fund II and has sole voting and dispositive power with regard to the securities held by DCVC Opportunity Fund II. The Reporting Person is a managing member of DCVC Opportunity Fund II GP and shares voting and dispositive power with respect to the securities held by DCVC Opportunity Fund II. The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":3246071,"source":{"system":"sec-edgar","filing":"0000950170-25-087771","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819994/000095017025087771/ownership.xml","form_type":"4"}},{"id":1105868,"issuer":{"id":1039,"kind":"organization","name":"Rocket Lab Corp","symbol":"RKLB"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-18T17:39:54.000Z","date":"2025-06-12","kind":"sale","planned":false,"acquired":false,"shares":57822,"price":26.4437,"value":1529027.6214,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price of the aggregate number of shares sold. These shares were sold in multiple transactions at prices ranging from $26.3750 to $26.6300, inclusive. The Reporting Person undertakes to provide to Rocket Lab Corporation (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the securities held by DCVC IV. The Reporting Person is a managing member of DCVC IV GP and shares voting and dispositive power with respect to the securities held by DCVC IV. The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":1320121,"source":{"system":"sec-edgar","filing":"0000950170-25-087771","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819994/000095017025087771/ownership.xml","form_type":"4"}},{"id":1361247,"issuer":{"id":1039,"kind":"organization","name":"Rocket Lab Corp","symbol":"RKLB"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-19T00:29:08.000Z","date":"2024-11-15","kind":"sale","planned":false,"acquired":false,"shares":2393001,"price":18.2143,"value":43586838.1143,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average price of the aggregate number of shares sold. These shares were sold in multiple transactions with 1,067,717 shares sold at prices ranging from $16.8800 to $17.8750, 1,893,911 shares sold at prices ranging from $17.8800 to $18.8750 and 404,565 shares sold at prices ranging from $19.0000 to $19.4750, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents securities held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opportunity Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opportunity Fund II GP\") is the general partner of DCVC Opportunity Fund II and has sole voting and dispositive power with regard to the securities held by DCVC Opportunity Fund II. The Reporting Person is a managing member of DCVC Opportunity Fund II GP and shares voting and dispositive power with respect to the securities held by DCVC Opportunity Fund II. The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":3388249,"source":{"system":"sec-edgar","filing":"0000950170-24-128168","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1819994/000095017024128168/ownership.xml","form_type":"4"}},{"id":1361246,"issuer":{"id":1039,"kind":"organization","name":"Rocket Lab Corp","symbol":"RKLB"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-19T00:29:08.000Z","date":"2024-11-15","kind":"sale","planned":false,"acquired":false,"shares":973192,"price":18.2143,"value":17726011.0456,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average price of the aggregate number of shares sold. These shares were sold in multiple transactions with 1,067,717 shares sold at prices ranging from $16.8800 to $17.8750, 1,893,911 shares sold at prices ranging from $17.8800 to $18.8750 and 404,565 shares sold at prices ranging from $19.0000 to $19.4750, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the securities held by DCVC IV. The Reporting Person is a managing member of DCVC IV GP and shares voting and dispositive power with respect to the securities held by DCVC IV. The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":1377943,"source":{"system":"sec-edgar","filing":"0000950170-24-128168","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819994/000095017024128168/ownership.xml","form_type":"4"}},{"id":1361245,"issuer":{"id":1039,"kind":"organization","name":"Rocket Lab Corp","symbol":"RKLB"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-19T00:29:08.000Z","date":"2024-11-14","kind":"sale","planned":false,"acquired":false,"shares":1421785,"price":17.7262,"value":25202845.267,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price of the aggregate number of shares sold. These shares were sold in multiple transactions with 1,782,427 shares sold at prices ranging from $17.2800 to $18.2700, 197,712 shares sold at prices ranging from $18.2800 to $19.2500 and 19,861 shares sold at prices ranging from $19.3000 to $19.6600, inclusive. The Reporting Person undertakes to provide to Rocket Lab USA, Inc. (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents securities held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opportunity Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opportunity Fund II GP\") is the general partner of DCVC Opportunity Fund II and has sole voting and dispositive power with regard to the securities held by DCVC Opportunity Fund II. The Reporting Person is a managing member of DCVC Opportunity Fund II GP and shares voting and dispositive power with respect to the securities held by DCVC Opportunity Fund II. The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":5781250,"source":{"system":"sec-edgar","filing":"0000950170-24-128168","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819994/000095017024128168/ownership.xml","form_type":"4"}},{"id":1361244,"issuer":{"id":1039,"kind":"organization","name":"Rocket Lab Corp","symbol":"RKLB"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-19T00:29:08.000Z","date":"2024-11-14","kind":"sale","planned":false,"acquired":false,"shares":578215,"price":17.7262,"value":10249554.733,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price of the aggregate number of shares sold. These shares were sold in multiple transactions with 1,782,427 shares sold at prices ranging from $17.2800 to $18.2700, 197,712 shares sold at prices ranging from $18.2800 to $19.2500 and 19,861 shares sold at prices ranging from $19.3000 to $19.6600, inclusive. The Reporting Person undertakes to provide to Rocket Lab USA, Inc. (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the securities held by DCVC IV. The Reporting Person is a managing member of DCVC IV GP and shares voting and dispositive power with respect to the securities held by DCVC IV. The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":2351135,"source":{"system":"sec-edgar","filing":"0000950170-24-128168","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819994/000095017024128168/ownership.xml","form_type":"4"}},{"id":2134422,"issuer":{"id":122955,"kind":"organization","name":"Zymergen Inc.","symbol":"ZY"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-19T19:15:33.000Z","date":"2022-10-19","kind":"disposition_to_issuer","acquired":false,"shares":4917734,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 24, 2022 (the \"Merger Agreement\"), by and among Ginkgo Bioworks Holdings, Inc. (\"Ginkgo\"), Pepper Merger Subsidiary Inc. and the Issuer, each share of the Issuer's common stock was cancelled and converted into a right to receive 0.9179 of a share of Class A common stock of Ginkgo, together with cash in lieu of any fractional shares of Class A common stock of Ginkgo."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held of record by DCVC Opportunity Fund, L.P. (\"DCVC Opportunity Fund\").  DCVC Opportunity Fund GP, LLC (\"DCVC Opportunity Fund GP\") is the general partner of DCVC Opportunity Fund and has sole voting and dispositive power with regard to the shares held by DCVC Opportunity Fund.  The Reporting Person is a managing member of DCVC Opportunity Fund GP and shares voting and dispositive power with respect to the shares held by DCVC Opportunity Fund.  The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001645842-22-000136","document":"wf-form4_166622131394812.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645842/000164584222000136/wf-form4_166622131394812.xml","form_type":"4"}},{"id":2134421,"issuer":{"id":122955,"kind":"organization","name":"Zymergen Inc.","symbol":"ZY"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-19T19:15:33.000Z","date":"2022-10-19","kind":"disposition_to_issuer","acquired":false,"shares":2448901,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 24, 2022 (the \"Merger Agreement\"), by and among Ginkgo Bioworks Holdings, Inc. (\"Ginkgo\"), Pepper Merger Subsidiary Inc. and the Issuer, each share of the Issuer's common stock was cancelled and converted into a right to receive 0.9179 of a share of Class A common stock of Ginkgo, together with cash in lieu of any fractional shares of Class A common stock of Ginkgo."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held of record by Data Collective II, L.P. (\"DCVC II\").  Data Collective II GP, LLC (\"DCVC II GP\") is the general partner of DCVC II and has sole voting and dispositive power with regard to the shares held by DCVC II. The Reporting Person is a managing member of DCVC II GP and shares voting and dispositive power with respect to the shares held by DCVC II.  The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001645842-22-000136","document":"wf-form4_166622131394812.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645842/000164584222000136/wf-form4_166622131394812.xml","form_type":"4"}},{"id":2168741,"issuer":{"id":110807,"kind":"organization","name":"Embark Technology, Inc.","symbol":"EMBK"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":3,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111559,"kind":"person","name":"Bogue Zachary","position":4,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-09-01T17:38:17.000Z","date":"2022-08-30","kind":"purchase","acquired":true,"shares":10000,"price":9.6388,"value":96388.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price calculated by the broker executing the purchases. These shares were purchased in multiple transactions, and the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects (i) 3,186,007 shares of Class A Common Stock held by Data Collective IV, L.P. (\"DCVC IV\"), (ii) 6,100 shares of Class A Common Stock held by Zachary Bogue and (iii) 20,000 shares of Class A Common Stock held by Matthew Ocko. Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the securities held by DCVC IV. The managing members of DCVC IV GP are Matthew Ocko and Zachary Bogue. Matthew Ocko and Zachary Bogue share voting and dispositive power with respect to the securities held by DCVC IV. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":3212107,"source":{"system":"sec-edgar","filing":"0001827980-22-000081","document":"wf-form4_166206828367843.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664972/000182798022000081/wf-form4_166206828367843.xml","form_type":"4"}},{"id":2176683,"issuer":{"id":110807,"kind":"organization","name":"Embark Technology, Inc.","symbol":"EMBK"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":3,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111559,"kind":"person","name":"Bogue Zachary","position":4,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-08-22T16:47:07.000Z","date":"2022-08-18","kind":"purchase","acquired":true,"shares":10000,"price":11.6383,"value":116383.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.51 to $11.68. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects (i) 3,186,007 shares of Class A Common Stock held by Data Collective IV, L.P. (\"DCVC IV\"), (ii) 6,100 shares of Class A Common Stock held by Zachary Bogue and (iii) 10,000 shares of Class A Common Stock held by Matthew Ocko. Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the securities held by DCVC IV. The managing members of DCVC IV GP are Matthew Ocko and Zachary Bogue. Matthew Ocko and Zachary Bogue share voting and dispositive power with respect to the securities held by DCVC IV. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":3202107,"source":{"system":"sec-edgar","filing":"0001827980-22-000078","document":"wf-form4_166120120791894.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664972/000182798022000078/wf-form4_166120120791894.xml","form_type":"4"}},{"id":2179084,"issuer":{"id":110807,"kind":"organization","name":"Embark Technology, Inc.","symbol":"EMBK"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":3,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111559,"kind":"person","name":"Bogue Zachary","position":4,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-08-18T21:06:06.000Z","date":"2022-08-16","kind":"purchase","acquired":true,"shares":122000,"price":0.8373,"value":102150.6,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.82 to $0.8594. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the amount of shares beneficially held following a 20-for-1 stock split effected by the Issuer on August 16, 2022, which was exempt from reporting pursuant to Rule 16a-9."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Reflects (i) 3,186,007 shares of Class A Common Stock held by Data Collective IV, L.P. (\"DCVC IV\") and (ii) 6,100 shares of Class A Common Stock held by Zachary Bogue. Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the securities held by DCVC IV. The managing members of DCVC IV GP are Matthew Ocko and Zachary Bogue. Matthew Ocko and Zachary Bogue share voting and dispositive power with respect to the securities held by DCVC IV. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":3192107,"source":{"system":"sec-edgar","filing":"0001827980-22-000076","document":"wf-form4_166087115119894.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664972/000182798022000076/wf-form4_166087115119894.xml","form_type":"4"}},{"id":2658202,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":137986,"kind":"organization","name":"DCVC Bio, L.P.","position":1,"cik":"0001735069","reported_name":"DCVC Bio, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":119945,"kind":"organization","name":"DCVC Bio GP, LLC","position":2,"cik":"0001735070","reported_name":"DCVC Bio GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137987,"kind":"organization","name":"JNK Capital Management, LLC","position":3,"cik":"0001836273","reported_name":"JNK Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137988,"kind":"organization","name":"ZNM Capital Management, LLC","position":4,"cik":"0001836103","reported_name":"ZNM Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111559,"kind":"person","name":"Bogue Zachary","position":5,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":6,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137989,"kind":"person","name":"Stead Kiersten","position":7,"cik":"0001836117","reported_name":"Stead Kiersten","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2021-06-22T22:13:35.000Z","date":"2021-06-18","kind":"other","acquired":true,"shares":73892,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 18, 2021, DCVC Bio, L.P. (\"DCVC Bio\") distributed, for no consideration, an aggregate of 5,000,000 Common Shares of the Issuer (\"DCVC Bio Shares\") to its limited partners and to DCVC Bio GP, LLC (\"DCVC Bio GP\"), its general partner, representing each such partner's pro rata interest in such DCVC Bio Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 18, 2021, DCVC Bio, L.P. (\"DCVC Bio\") distributed, for no consideration, an aggregate of 5,000,000 Common Shares of the Issuer (\"DCVC Bio Shares\") to its limited partners and to DCVC Bio GP, LLC (\"DCVC Bio GP\"), its general partner, representing each such partner's pro rata interest in such DCVC Bio Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held by DCVC Bio GP.  JNK and ZNM are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio GP. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio GP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continued from Footnote 4) Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any."}],"balance_after":73892,"source":{"system":"sec-edgar","filing":"0001209191-21-042496","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1703057/000120919121042496/doc4.xml","form_type":"4"}},{"id":2658201,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":137986,"kind":"organization","name":"DCVC Bio, L.P.","position":1,"cik":"0001735069","reported_name":"DCVC Bio, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":119945,"kind":"organization","name":"DCVC Bio GP, LLC","position":2,"cik":"0001735070","reported_name":"DCVC Bio GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137987,"kind":"organization","name":"JNK Capital Management, LLC","position":3,"cik":"0001836273","reported_name":"JNK Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137988,"kind":"organization","name":"ZNM Capital Management, LLC","position":4,"cik":"0001836103","reported_name":"ZNM Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111559,"kind":"person","name":"Bogue Zachary","position":5,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":6,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137989,"kind":"person","name":"Stead Kiersten","position":7,"cik":"0001836117","reported_name":"Stead Kiersten","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2021-06-22T22:13:35.000Z","date":"2021-06-18","kind":"other","acquired":false,"shares":5000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 18, 2021, DCVC Bio, L.P. (\"DCVC Bio\") distributed, for no consideration, an aggregate of 5,000,000 Common Shares of the Issuer (\"DCVC Bio Shares\") to its limited partners and to DCVC Bio GP, LLC (\"DCVC Bio GP\"), its general partner, representing each such partner's pro rata interest in such DCVC Bio Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 18, 2021, DCVC Bio, L.P. (\"DCVC Bio\") distributed, for no consideration, an aggregate of 5,000,000 Common Shares of the Issuer (\"DCVC Bio Shares\") to its limited partners and to DCVC Bio GP, LLC (\"DCVC Bio GP\"), its general partner, representing each such partner's pro rata interest in such DCVC Bio Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held by DCVC Bio. DCVC Bio GP is the general partner of DCVC Bio and has sole voting and dispositive power with regard to the securities held by DCVC Bio. JNK Capital Management, LLC (\"JNK\") and ZNM Capital Management, LLC (\"ZNM\") are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any."}],"balance_after":24105761,"source":{"system":"sec-edgar","filing":"0001209191-21-042496","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703057/000120919121042496/doc4.xml","form_type":"4"}},{"id":2739322,"issuer":{"id":122955,"kind":"organization","name":"Zymergen Inc.","symbol":"ZY"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true}}],"security":"Series D Preferred Stock","published_at":"2021-04-26T18:56:42.000Z","date":"2021-04-26","kind":"exercise","acquired":false,"shares":223945,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held of record by Data Collective II, L.P. (\"DCVC II\").  Data Collective II GP, LLC (\"DCVC II GP\") is the general partner of DCVC II and has sole voting and dispositive power with regard to the shares held by DCVC II. The Reporting Person is a managing member of DCVC II GP and shares voting and dispositive power with respect to the shares held by DCVC II.  The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":223945},"source":{"system":"sec-edgar","filing":"0001140361-21-014360","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1645842/000114036121014360/form4.xml","form_type":"4"}},{"id":2739321,"issuer":{"id":122955,"kind":"organization","name":"Zymergen Inc.","symbol":"ZY"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true}}],"security":"Series C Preferred Stock","published_at":"2021-04-26T18:56:42.000Z","date":"2021-04-26","kind":"exercise","acquired":false,"shares":294401,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by DCVC Opportunity Fund, L.P. (\"DCVC Opportunity Fund\").  DCVC Opportunity Fund GP, LLC (\"DCVC Opportunity Fund GP\") is the general partner of DCVC Opportunity Fund and has sole voting and dispositive power with regard to the shares held by DCVC Opportunity Fund.  The Reporting Person is a managing member of DCVC Opportunity Fund GP and shares voting and dispositive power with respect to the shares held by DCVC Opportunity Fund.  The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":294401},"source":{"system":"sec-edgar","filing":"0001140361-21-014360","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1645842/000114036121014360/form4.xml","form_type":"4"}},{"id":2739320,"issuer":{"id":122955,"kind":"organization","name":"Zymergen Inc.","symbol":"ZY"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true}}],"security":"Series B Preferred Stock","published_at":"2021-04-26T18:56:42.000Z","date":"2021-04-26","kind":"exercise","acquired":false,"shares":1684397,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Each share of Series B Preferred Stock converted automatically into 1.0015 shares of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series B Preferred Stock converted automatically into 1.0015 shares of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series B Preferred Stock converted automatically into 1.0015 shares of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series B Preferred Stock converted automatically into 1.0015 shares of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by DCVC Opportunity Fund, L.P. (\"DCVC Opportunity Fund\").  DCVC Opportunity Fund GP, LLC (\"DCVC Opportunity Fund GP\") is the general partner of DCVC Opportunity Fund and has sole voting and dispositive power with regard to the shares held by DCVC Opportunity Fund.  The Reporting Person is a managing member of DCVC Opportunity Fund GP and shares voting and dispositive power with respect to the shares held by DCVC Opportunity Fund.  The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1687050},"source":{"system":"sec-edgar","filing":"0001140361-21-014360","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1645842/000114036121014360/form4.xml","form_type":"4"}},{"id":2739319,"issuer":{"id":122955,"kind":"organization","name":"Zymergen Inc.","symbol":"ZY"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true}}],"security":"Series A-1 Preferred Stock","published_at":"2021-04-26T18:56:42.000Z","date":"2021-04-26","kind":"exercise","acquired":false,"shares":2014506,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held of record by Data Collective II, L.P. (\"DCVC II\").  Data Collective II GP, LLC (\"DCVC II GP\") is the general partner of DCVC II and has sole voting and dispositive power with regard to the shares held by DCVC II. The Reporting Person is a managing member of DCVC II GP and shares voting and dispositive power with respect to the shares held by DCVC II.  The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2014506},"source":{"system":"sec-edgar","filing":"0001140361-21-014360","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1645842/000114036121014360/form4.xml","form_type":"4"}},{"id":2739318,"issuer":{"id":122955,"kind":"organization","name":"Zymergen Inc.","symbol":"ZY"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true}}],"security":"Series A Preferred Stock","published_at":"2021-04-26T18:56:42.000Z","date":"2021-04-26","kind":"exercise","acquired":false,"shares":2936283,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by DCVC Opportunity Fund, L.P. (\"DCVC Opportunity Fund\").  DCVC Opportunity Fund GP, LLC (\"DCVC Opportunity Fund GP\") is the general partner of DCVC Opportunity Fund and has sole voting and dispositive power with regard to the shares held by DCVC Opportunity Fund.  The Reporting Person is a managing member of DCVC Opportunity Fund GP and shares voting and dispositive power with respect to the shares held by DCVC Opportunity Fund.  The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2936283},"source":{"system":"sec-edgar","filing":"0001140361-21-014360","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1645842/000114036121014360/form4.xml","form_type":"4"}},{"id":2739317,"issuer":{"id":122955,"kind":"organization","name":"Zymergen Inc.","symbol":"ZY"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true}}],"security":"Series A Preferred Stock","published_at":"2021-04-26T18:56:42.000Z","date":"2021-04-26","kind":"exercise","acquired":false,"shares":210450,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held of record by Data Collective II, L.P. (\"DCVC II\").  Data Collective II GP, LLC (\"DCVC II GP\") is the general partner of DCVC II and has sole voting and dispositive power with regard to the shares held by DCVC II. The Reporting Person is a managing member of DCVC II GP and shares voting and dispositive power with respect to the shares held by DCVC II.  The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":210450},"source":{"system":"sec-edgar","filing":"0001140361-21-014360","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1645842/000114036121014360/form4.xml","form_type":"4"}},{"id":2739316,"issuer":{"id":122955,"kind":"organization","name":"Zymergen Inc.","symbol":"ZY"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-04-26T18:56:42.000Z","date":"2021-04-26","kind":"exercise","acquired":true,"shares":223945,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held of record by Data Collective II, L.P. (\"DCVC II\").  Data Collective II GP, LLC (\"DCVC II GP\") is the general partner of DCVC II and has sole voting and dispositive power with regard to the shares held by DCVC II. The Reporting Person is a managing member of DCVC II GP and shares voting and dispositive power with respect to the shares held by DCVC II.  The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":2448901,"source":{"system":"sec-edgar","filing":"0001140361-21-014360","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1645842/000114036121014360/form4.xml","form_type":"4"}},{"id":2739315,"issuer":{"id":122955,"kind":"organization","name":"Zymergen Inc.","symbol":"ZY"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-04-26T18:56:42.000Z","date":"2021-04-26","kind":"exercise","acquired":true,"shares":294401,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by DCVC Opportunity Fund, L.P. (\"DCVC Opportunity Fund\").  DCVC Opportunity Fund GP, LLC (\"DCVC Opportunity Fund GP\") is the general partner of DCVC Opportunity Fund and has sole voting and dispositive power with regard to the shares held by DCVC Opportunity Fund.  The Reporting Person is a managing member of DCVC Opportunity Fund GP and shares voting and dispositive power with respect to the shares held by DCVC Opportunity Fund.  The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":4917734,"source":{"system":"sec-edgar","filing":"0001140361-21-014360","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645842/000114036121014360/form4.xml","form_type":"4"}},{"id":2739314,"issuer":{"id":122955,"kind":"organization","name":"Zymergen Inc.","symbol":"ZY"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-04-26T18:56:42.000Z","date":"2021-04-26","kind":"exercise","acquired":true,"shares":1687050,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B Preferred Stock converted automatically into 1.0015 shares of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by DCVC Opportunity Fund, L.P. (\"DCVC Opportunity Fund\").  DCVC Opportunity Fund GP, LLC (\"DCVC Opportunity Fund GP\") is the general partner of DCVC Opportunity Fund and has sole voting and dispositive power with regard to the shares held by DCVC Opportunity Fund.  The Reporting Person is a managing member of DCVC Opportunity Fund GP and shares voting and dispositive power with respect to the shares held by DCVC Opportunity Fund.  The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":4623333,"source":{"system":"sec-edgar","filing":"0001140361-21-014360","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645842/000114036121014360/form4.xml","form_type":"4"}},{"id":2739313,"issuer":{"id":122955,"kind":"organization","name":"Zymergen Inc.","symbol":"ZY"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-04-26T18:56:42.000Z","date":"2021-04-26","kind":"exercise","acquired":true,"shares":2014506,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held of record by Data Collective II, L.P. (\"DCVC II\").  Data Collective II GP, LLC (\"DCVC II GP\") is the general partner of DCVC II and has sole voting and dispositive power with regard to the shares held by DCVC II. The Reporting Person is a managing member of DCVC II GP and shares voting and dispositive power with respect to the shares held by DCVC II.  The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":2224956,"source":{"system":"sec-edgar","filing":"0001140361-21-014360","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645842/000114036121014360/form4.xml","form_type":"4"}},{"id":2739312,"issuer":{"id":122955,"kind":"organization","name":"Zymergen Inc.","symbol":"ZY"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-04-26T18:56:42.000Z","date":"2021-04-26","kind":"exercise","acquired":true,"shares":2936283,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by DCVC Opportunity Fund, L.P. (\"DCVC Opportunity Fund\").  DCVC Opportunity Fund GP, LLC (\"DCVC Opportunity Fund GP\") is the general partner of DCVC Opportunity Fund and has sole voting and dispositive power with regard to the shares held by DCVC Opportunity Fund.  The Reporting Person is a managing member of DCVC Opportunity Fund GP and shares voting and dispositive power with respect to the shares held by DCVC Opportunity Fund.  The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":2936283,"source":{"system":"sec-edgar","filing":"0001140361-21-014360","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645842/000114036121014360/form4.xml","form_type":"4"}},{"id":2739311,"issuer":{"id":122955,"kind":"organization","name":"Zymergen Inc.","symbol":"ZY"},"owners":[{"id":75187,"kind":"person","name":"Ocko Matthew","position":1,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-04-26T18:56:42.000Z","date":"2021-04-26","kind":"exercise","acquired":true,"shares":210450,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A, Series A-1, Series C and Series D Preferred Stock converted automatically into one share of the Issuer's common stock for no additional consideration upon the completion of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held of record by Data Collective II, L.P. (\"DCVC II\").  Data Collective II GP, LLC (\"DCVC II GP\") is the general partner of DCVC II and has sole voting and dispositive power with regard to the shares held by DCVC II. The Reporting Person is a managing member of DCVC II GP and shares voting and dispositive power with respect to the shares held by DCVC II.  The Reporting Person disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares, except to the extent of his indirect pecuniary interest therein, if any."}],"balance_after":210450,"source":{"system":"sec-edgar","filing":"0001140361-21-014360","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645842/000114036121014360/form4.xml","form_type":"4"}},{"id":2742030,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":3726963,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held of record by DCVC V, L.P. (\"DCVC V\"). DCVC V GP, LLC (\"DCVC V GP\") is the general partner of DCVC V and has sole voting and dispositive power with regard to the shares held by DCVC V. Matthew Ocko and Zachary Bogue are the managing members of DCVC V GP and share voting and dispositive power with respect to the shares held by DCVC V. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3726963},"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742029,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":730353,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opp Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opp Fund II GP\") is the general partner of DCVC Opp Fund II and has sole voting and dispositive power with regard to the shares held by DCVC Opp Fund II. Matthew Ocko and Zachary Bogue are the managing members of DCVC Opp Fund II GP and share voting and dispositive power with respect to the shares held by DCVC Opp Fund II. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":730353},"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742028,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":1095529,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the shares held by DCVC IV. Matthew Ocko and Zachary Bogue are the managing members of DCVC IV GP and share voting and dispositive power with respect to the shares held by DCVC IV. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1095529},"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742027,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":3220788,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opp Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opp Fund II GP\") is the general partner of DCVC Opp Fund II and has sole voting and dispositive power with regard to the shares held by DCVC Opp Fund II. Matthew Ocko and Zachary Bogue are the managing members of DCVC Opp Fund II GP and share voting and dispositive power with respect to the shares held by DCVC Opp Fund II. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3220788},"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742026,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":1073595,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the shares held by DCVC IV. Matthew Ocko and Zachary Bogue are the managing members of DCVC IV GP and share voting and dispositive power with respect to the shares held by DCVC IV. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1073595},"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742025,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":3771996,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the shares held by DCVC IV. Matthew Ocko and Zachary Bogue are the managing members of DCVC IV GP and share voting and dispositive power with respect to the shares held by DCVC IV. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3771996},"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742024,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"other","acquired":true,"shares":3726963,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held of record by DCVC V, L.P. (\"DCVC V\"). DCVC V GP, LLC (\"DCVC V GP\") is the general partner of DCVC V and has sole voting and dispositive power with regard to the shares held by DCVC V. Matthew Ocko and Zachary Bogue are the managing members of DCVC V GP and share voting and dispositive power with respect to the shares held by DCVC V. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":3726963,"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742023,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"other","acquired":false,"shares":3726963,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held of record by DCVC V, L.P. (\"DCVC V\"). DCVC V GP, LLC (\"DCVC V GP\") is the general partner of DCVC V and has sole voting and dispositive power with regard to the shares held by DCVC V. Matthew Ocko and Zachary Bogue are the managing members of DCVC V GP and share voting and dispositive power with respect to the shares held by DCVC V. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742022,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"exercise","acquired":true,"shares":3726963,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held of record by DCVC V, L.P. (\"DCVC V\"). DCVC V GP, LLC (\"DCVC V GP\") is the general partner of DCVC V and has sole voting and dispositive power with regard to the shares held by DCVC V. Matthew Ocko and Zachary Bogue are the managing members of DCVC V GP and share voting and dispositive power with respect to the shares held by DCVC V. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":3726963,"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742021,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"other","acquired":true,"shares":3951141,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opp Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opp Fund II GP\") is the general partner of DCVC Opp Fund II and has sole voting and dispositive power with regard to the shares held by DCVC Opp Fund II. Matthew Ocko and Zachary Bogue are the managing members of DCVC Opp Fund II GP and share voting and dispositive power with respect to the shares held by DCVC Opp Fund II. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":3951141,"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742020,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"other","acquired":false,"shares":3951141,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opp Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opp Fund II GP\") is the general partner of DCVC Opp Fund II and has sole voting and dispositive power with regard to the shares held by DCVC Opp Fund II. Matthew Ocko and Zachary Bogue are the managing members of DCVC Opp Fund II GP and share voting and dispositive power with respect to the shares held by DCVC Opp Fund II. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742019,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"exercise","acquired":true,"shares":3951141,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by DCVC Opportunity Fund II, L.P. (\"DCVC Opp Fund II\"). DCVC Opportunity Fund II GP, LLC (\"DCVC Opp Fund II GP\") is the general partner of DCVC Opp Fund II and has sole voting and dispositive power with regard to the shares held by DCVC Opp Fund II. Matthew Ocko and Zachary Bogue are the managing members of DCVC Opp Fund II GP and share voting and dispositive power with respect to the shares held by DCVC Opp Fund II. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":3951141,"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742018,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"other","acquired":true,"shares":5941120,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the shares held by DCVC IV. Matthew Ocko and Zachary Bogue are the managing members of DCVC IV GP and share voting and dispositive power with respect to the shares held by DCVC IV. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":5941120,"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742017,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"other","acquired":false,"shares":5941120,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the shares held by DCVC IV. Matthew Ocko and Zachary Bogue are the managing members of DCVC IV GP and share voting and dispositive power with respect to the shares held by DCVC IV. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2742016,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":124085,"kind":"organization","name":"Data Collective IV, L.P.","position":1,"cik":"0001664972","reported_name":"Data Collective IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":117937,"kind":"organization","name":"Data Collective IV GP, LLC","position":2,"cik":"0001664974","reported_name":"Data Collective IV GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140098,"kind":"organization","name":"DCVC V GP, LLC","position":3,"cik":"0001770616","reported_name":"DCVC V GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140099,"kind":"organization","name":"DCVC V, L.P.","position":4,"cik":"0001770617","reported_name":"DCVC V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118086,"kind":"organization","name":"DCVC Opportunity Fund II GP, LLC","position":5,"cik":"0001668343","reported_name":"DCVC Opportunity Fund II GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":140100,"kind":"organization","name":"DCVC Opportunity Fund II, L.P.","position":6,"cik":"0001668344","reported_name":"DCVC Opportunity Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":7,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-22T19:46:41.000Z","date":"2021-04-20","kind":"exercise","acquired":true,"shares":5941120,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held of record by Data Collective IV, L.P. (\"DCVC IV\"). Data Collective IV GP, LLC (\"DCVC IV GP\") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the shares held by DCVC IV. Matthew Ocko and Zachary Bogue are the managing members of DCVC IV GP and share voting and dispositive power with respect to the shares held by DCVC IV. Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any."}],"balance_after":5941120,"source":{"system":"sec-edgar","filing":"0001209191-21-028024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668344/000120919121028024/doc4.xml","form_type":"4"}},{"id":2939104,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":137986,"kind":"organization","name":"DCVC Bio, L.P.","position":1,"cik":"0001735069","reported_name":"DCVC Bio, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111559,"kind":"person","name":"Bogue Zachary","position":2,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":119945,"kind":"organization","name":"DCVC Bio GP, LLC","position":3,"cik":"0001735070","reported_name":"DCVC Bio GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137987,"kind":"organization","name":"JNK Capital Management, LLC","position":4,"cik":"0001836273","reported_name":"JNK Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":5,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137989,"kind":"person","name":"Stead Kiersten","position":6,"cik":"0001836117","reported_name":"Stead Kiersten","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137988,"kind":"organization","name":"ZNM Capital Management, LLC","position":7,"cik":"0001836103","reported_name":"ZNM Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Note","published_at":"2020-12-18T01:45:44.000Z","date":"2020-12-15","kind":"exercise","acquired":false,"price":0,"reported_value":500000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The convertible promissory note (\"Convertible Note\") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The convertible promissory note (\"Convertible Note\") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held by DCVC Bio, L.P. (\"DCVC Bio\"). DCVC Bio GP, LLC (\"DCVC Bio GP\") is the general partner of DCVC Bio and has sole voting and dispositive power with regard to the securities held by DCVC Bio. JNK Capital Management, LLC (\"JNK\") and ZNM Capital Management, LLC (\"ZNM\") are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"exercise_price":17,"underlying":"Common Shares","underlying_shares":29411},"source":{"system":"sec-edgar","filing":"0001209191-20-064259","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1703057/000120919120064259/doc4.xml","form_type":"4"}},{"id":2939103,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":137986,"kind":"organization","name":"DCVC Bio, L.P.","position":1,"cik":"0001735069","reported_name":"DCVC Bio, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111559,"kind":"person","name":"Bogue Zachary","position":2,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":119945,"kind":"organization","name":"DCVC Bio GP, LLC","position":3,"cik":"0001735070","reported_name":"DCVC Bio GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137987,"kind":"organization","name":"JNK Capital Management, LLC","position":4,"cik":"0001836273","reported_name":"JNK Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":5,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137989,"kind":"person","name":"Stead Kiersten","position":6,"cik":"0001836117","reported_name":"Stead Kiersten","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137988,"kind":"organization","name":"ZNM Capital Management, LLC","position":7,"cik":"0001836103","reported_name":"ZNM Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A2 Preferred Shares","published_at":"2020-12-18T01:45:44.000Z","date":"2020-12-15","kind":"exercise","acquired":false,"shares":802371,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the \"Preferred Shares\") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering (\"IPO\"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the \"Preferred Shares\") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering (\"IPO\"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the \"Preferred Shares\") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering (\"IPO\"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held by DCVC Bio, L.P. (\"DCVC Bio\"). DCVC Bio GP, LLC (\"DCVC Bio GP\") is the general partner of DCVC Bio and has sole voting and dispositive power with regard to the securities held by DCVC Bio. JNK Capital Management, LLC (\"JNK\") and ZNM Capital Management, LLC (\"ZNM\") are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":8023710},"source":{"system":"sec-edgar","filing":"0001209191-20-064259","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1703057/000120919120064259/doc4.xml","form_type":"4"}},{"id":2939102,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":137986,"kind":"organization","name":"DCVC Bio, L.P.","position":1,"cik":"0001735069","reported_name":"DCVC Bio, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111559,"kind":"person","name":"Bogue Zachary","position":2,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":119945,"kind":"organization","name":"DCVC Bio GP, LLC","position":3,"cik":"0001735070","reported_name":"DCVC Bio GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137987,"kind":"organization","name":"JNK Capital Management, LLC","position":4,"cik":"0001836273","reported_name":"JNK Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":5,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137989,"kind":"person","name":"Stead Kiersten","position":6,"cik":"0001836117","reported_name":"Stead Kiersten","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137988,"kind":"organization","name":"ZNM Capital Management, LLC","position":7,"cik":"0001836103","reported_name":"ZNM Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A1 Preferred Shares","published_at":"2020-12-18T01:45:44.000Z","date":"2020-12-15","kind":"exercise","acquired":false,"shares":2105264,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the \"Preferred Shares\") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering (\"IPO\"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the \"Preferred Shares\") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering (\"IPO\"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the \"Preferred Shares\") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering (\"IPO\"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held by DCVC Bio, L.P. (\"DCVC Bio\"). DCVC Bio GP, LLC (\"DCVC Bio GP\") is the general partner of DCVC Bio and has sole voting and dispositive power with regard to the securities held by DCVC Bio. JNK Capital Management, LLC (\"JNK\") and ZNM Capital Management, LLC (\"ZNM\") are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":21052640},"source":{"system":"sec-edgar","filing":"0001209191-20-064259","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1703057/000120919120064259/doc4.xml","form_type":"4"}},{"id":2939101,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":137986,"kind":"organization","name":"DCVC Bio, L.P.","position":1,"cik":"0001735069","reported_name":"DCVC Bio, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111559,"kind":"person","name":"Bogue Zachary","position":2,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":119945,"kind":"organization","name":"DCVC Bio GP, LLC","position":3,"cik":"0001735070","reported_name":"DCVC Bio GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137987,"kind":"organization","name":"JNK Capital Management, LLC","position":4,"cik":"0001836273","reported_name":"JNK Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":5,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137989,"kind":"person","name":"Stead Kiersten","position":6,"cik":"0001836117","reported_name":"Stead Kiersten","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137988,"kind":"organization","name":"ZNM Capital Management, LLC","position":7,"cik":"0001836103","reported_name":"ZNM Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2020-12-18T01:45:44.000Z","date":"2020-12-15","kind":"exercise","acquired":true,"shares":29411,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The convertible promissory note (\"Convertible Note\") had a maturity date of October 30, 2025 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held by DCVC Bio, L.P. (\"DCVC Bio\"). DCVC Bio GP, LLC (\"DCVC Bio GP\") is the general partner of DCVC Bio and has sole voting and dispositive power with regard to the securities held by DCVC Bio. JNK Capital Management, LLC (\"JNK\") and ZNM Capital Management, LLC (\"ZNM\") are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any."}],"balance_after":29105761,"source":{"system":"sec-edgar","filing":"0001209191-20-064259","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1703057/000120919120064259/doc4.xml","form_type":"4"}},{"id":2939100,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":137986,"kind":"organization","name":"DCVC Bio, L.P.","position":1,"cik":"0001735069","reported_name":"DCVC Bio, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111559,"kind":"person","name":"Bogue Zachary","position":2,"cik":"0001836157","reported_name":"Bogue Zachary","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":119945,"kind":"organization","name":"DCVC Bio GP, LLC","position":3,"cik":"0001735070","reported_name":"DCVC Bio GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137987,"kind":"organization","name":"JNK Capital Management, LLC","position":4,"cik":"0001836273","reported_name":"JNK Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75187,"kind":"person","name":"Ocko Matthew","position":5,"cik":"0001836089","reported_name":"Ocko Matthew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137989,"kind":"person","name":"Stead Kiersten","position":6,"cik":"0001836117","reported_name":"Stead Kiersten","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":137988,"kind":"organization","name":"ZNM Capital Management, LLC","position":7,"cik":"0001836103","reported_name":"ZNM Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2020-12-18T01:45:44.000Z","date":"2020-12-15","kind":"exercise","acquired":true,"shares":29076350,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the \"Preferred Shares\") were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering (\"IPO\"). The Preferred Shares converted into Common Shares at a 1:10 ratio upon the closing of the IPO without payment of additional consideration. The Preferred Shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held by DCVC Bio, L.P. (\"DCVC Bio\"). DCVC Bio GP, LLC (\"DCVC Bio GP\") is the general partner of DCVC Bio and has sole voting and dispositive power with regard to the securities held by DCVC Bio. JNK Capital Management, LLC (\"JNK\") and ZNM Capital Management, LLC (\"ZNM\") are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any."}],"balance_after":29076350,"source":{"system":"sec-edgar","filing":"0001209191-20-064259","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703057/000120919120064259/doc4.xml","form_type":"4"}}]}